WO2010054331A4 - Microrna-mediated regulation of ubc9 expression in cancer cells - Google Patents

Microrna-mediated regulation of ubc9 expression in cancer cells Download PDF

Info

Publication number
WO2010054331A4
WO2010054331A4 PCT/US2009/063751 US2009063751W WO2010054331A4 WO 2010054331 A4 WO2010054331 A4 WO 2010054331A4 US 2009063751 W US2009063751 W US 2009063751W WO 2010054331 A4 WO2010054331 A4 WO 2010054331A4
Authority
WO
WIPO (PCT)
Prior art keywords
molecule
composition according
group
microrna
nucleotide sequence
Prior art date
Application number
PCT/US2009/063751
Other languages
French (fr)
Other versions
WO2010054331A1 (en
Inventor
Yin-Yuan Mo
Original Assignee
Board Of Trustees Of Southern Illinois University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Board Of Trustees Of Southern Illinois University filed Critical Board Of Trustees Of Southern Illinois University
Priority to CA2742991A priority Critical patent/CA2742991A1/en
Priority to AU2009313258A priority patent/AU2009313258A1/en
Priority to EP09825565A priority patent/EP2358372A1/en
Publication of WO2010054331A1 publication Critical patent/WO2010054331A1/en
Publication of WO2010054331A4 publication Critical patent/WO2010054331A4/en
Priority to IL212552A priority patent/IL212552A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Novel small expressed microRNA molecules associated with physiological regulatory mechanisms and particularly in developmental control are provided herein. More particularly, the present invention relates to microRNA molecules that suppress cancerous cell growth and other cancer-related disorders by suppressing tumor promoting factors such as, for example, Ubc9. Further, it is contemplated that the use of the microRNA molecules hereof will improve the diagnoses, prevention and/or treatment and also the identification and development of pharmaceuticals that are effective in connection with cancer cell growth.

Claims

AMENDED CLAIMS received by the International Bureau on 14 June 2010 (14.06.2010)What is claimed is:
1. A method for preventing or treating cancer cell growth comprising administering a therapeutically-effective amount of an isolated nucleic acid molecule selected from the group consisting of (a) the nucleotide sequence selected from the group consisting of SEQ ED NOS: 1- 17; (b) a nucleotide sequence selected from the group consisting of the complement of (a); and (c) a nucleotide sequence which has a sequence identity of at least 90% to SEQ ID NOS: 1-17 or the complement of SEQ ID NOS: 1-17.
2. The method according to claim 1, wherein said molecule is a microRNA.
3. The method according to claim 1, wherein said molecule is single-stranded.
4. The method according to claim 1, wherein said molecule is at least partially double-stranded.
5. The method according to claim 1, wherein said molecule is selected from the group consisting of RNA, DNA and modified nucleotide molecules.
6. The method according to claim 5, wherein said molecule comprises at least one modified nucleotide.
7. The method according to claim 1, wherein said nucleotide sequence in part (c) has an identity of at least 95% to a sequence of (a) or (b).
8. The method according to claim 1, wherein said at least one nucleic acid molecule is in combination with a pharmaceutically acceptable carrier.
9. The method according to claim 8, wherein said pharmaceutically acceptable carrier is suitable for diagnostic applications.
10. The method according to claim 8, wherein said pharmaceutically acceptable carrier is suitable for therapeutic applications.
11. A pharmaceutical composition for diagnosing, preventing or treating cancer cell growth comprising administering an isolated nucleic acid molecule selected from the group
32 consisting of (a) the nucleotide sequence selected from the group consisting of SEQ ID NOS: 1- 17; (b) a nucleotide sequence selected from the group consisting of the complement of (a); and (c) a nucleotide sequence which has a sequence identity of at least 90% to SEQ ID NOS: 1-17 or the complement of SEQ ID NOS: 1-17.
12. The composition according to claim 11, wherein said molecule is a microRNA.
13. The composition according to claim 11, wherein said molecule is single-stranded.
14. The composition according to claim 11, wherein said molecule is at least partially double-stranded.
15. The composition according to claim 11, wherein said molecule is selected from the group consisting of RNA, DNA and modified nucleotide molecules.
16. The composition according to claim 15, wherein said molecule comprises at least one modified nucleotide.
17. The composition according to claim 11, wherein said nucleotide sequence in part (c) has an identity of at least 95% to a sequence of (a) or (b).
18. The composition according to claim 11, wherein said at least one nucleic acid molecule is in combination with a pharmaceutically acceptable carrier.
19. The composition according to claim 18, wherein said pharmaceutically acceptable carrier is suitable for diagnostic applications.
20. The composition according to claim 18, wherein said pharmaceutically acceptable carrier is suitable for therapeutic applications.
21. A diagnostic kit for determining or classifying microRNA- associated pathogenic disorders characterized by differential expression of microRNA-molecules or microRNA- molecule patterns comprising the nucleic acid molecule of claim 11.
33
PCT/US2009/063751 2008-11-07 2009-11-09 Microrna-mediated regulation of ubc9 expression in cancer cells WO2010054331A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA2742991A CA2742991A1 (en) 2008-11-07 2009-11-09 Microrna-mediated regulation of ubc9 expression in cancer cells
AU2009313258A AU2009313258A1 (en) 2008-11-07 2009-11-09 MicroRNA-mediated regulation of Ubc9 expression in cancer cells
EP09825565A EP2358372A1 (en) 2008-11-07 2009-11-09 Microrna-mediated regulation of ubc9 expression in cancer cells
IL212552A IL212552A0 (en) 2008-11-07 2011-04-28 Microrna-mediated regulation of ubc9 expression in cancer cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19867208P 2008-11-07 2008-11-07
US61/198,672 2008-11-07

Publications (2)

Publication Number Publication Date
WO2010054331A1 WO2010054331A1 (en) 2010-05-14
WO2010054331A4 true WO2010054331A4 (en) 2010-08-19

Family

ID=42153297

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/063751 WO2010054331A1 (en) 2008-11-07 2009-11-09 Microrna-mediated regulation of ubc9 expression in cancer cells

Country Status (5)

Country Link
EP (1) EP2358372A1 (en)
AU (1) AU2009313258A1 (en)
CA (1) CA2742991A1 (en)
IL (1) IL212552A0 (en)
WO (1) WO2010054331A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070259349A1 (en) * 2006-05-04 2007-11-08 Itzhak Bentwich Bladder cancer-related nucleic acids
US20060185027A1 (en) * 2004-12-23 2006-08-17 David Bartel Systems and methods for identifying miRNA targets and for altering miRNA and target expression
US7955848B2 (en) * 2006-04-03 2011-06-07 Trustees Of Dartmouth College MicroRNA biomarkers for human breast and lung cancer

Also Published As

Publication number Publication date
IL212552A0 (en) 2011-06-30
WO2010054331A1 (en) 2010-05-14
EP2358372A1 (en) 2011-08-24
AU2009313258A1 (en) 2010-05-14
CA2742991A1 (en) 2010-05-14

Similar Documents

Publication Publication Date Title
JP2017519766A5 (en)
WO2015193651A4 (en) Reducing intron retention
CN108350454A (en) Allele selective gene editing and application thereof
EP2818550A1 (en) Gene expression and pain
US20180153919A1 (en) Organic compositions to treat kras-related diseases
BRPI0811170B8 (en) RNA oligonucleotides and hydroxymethyl substituted RNA complexes
DE19956568A1 (en) Method and medicament for inhibiting the expression of a given gene
WO2010141511A3 (en) Polynucleotides for multivalent rna interference, compositions and methods of use thereof
WO2012024396A3 (en) Compositions and methods for delivering nucleic acid molecules and treating cancer
WO2008132234A4 (en) Rna antagonist compounds for the modulation of beta-catenin
EA201591590A1 (en) MODIFIED oligonucleotides TRF-BETA
MX2024001181A (en) Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene.
WO2008109381A3 (en) Nucleic acid compounds for inhibiting hif1a gene expression and uses thereof
Kameshima et al. Conjugation of peptide nucleic acid with a pyrrole/imidazole polyamide to specifically recognize and cleave DNA.
Ma et al. Identification and cleavage site analysis of DNA sequences bound strongly by bleomycin
CN112996913B (en) Oligomeric nucleic acid molecules and uses thereof
Yuan et al. Overexpression of microRNA-21-5p prevents the oxidative stress-induced apoptosis of RSC96 cells by suppressing autophagy
Hu et al. Expression of the microRNA‑30 family in pulmonary arterial hypertension and the role of microRNA‑30d‑5p in the regulation of pulmonary arterial smooth muscle cell toxicity and apoptosis
CN105861551A (en) Vector for jointly expressing MicroRNAs to inhibit breast cancer cell proliferation and construction method and application thereof
WO2009043759A3 (en) Short rna antagonist compounds for the modulation of hif1alpha
WO2008001219A3 (en) Cancer therapy using bcl-xl-specific sina
WO2010054331A4 (en) Microrna-mediated regulation of ubc9 expression in cancer cells
Zamani et al. Dendrosomal curcumin upregulates expression of the long non-coding RNA gene MEG3 in U87MG Glioblastoma cells
WO2008109548A3 (en) Nucleic acid compounds for inhibiting tgfb gene expression and uses thereof
CN113260702B (en) Oligomeric nucleic acid molecules and their use in the treatment of acute intermittent porphyria

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09825565

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009313258

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 592476

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 212552

Country of ref document: IL

Ref document number: 2011534938

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2742991

Country of ref document: CA

Ref document number: MX/A/2011/004848

Country of ref document: MX

Ref document number: 1020117010381

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009825565

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2009313258

Country of ref document: AU

Date of ref document: 20091109

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: JP